HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017
Authors:
- Carlos Henrique Valente MoreiraCMCarlos Henrique Valente Moreira
- Tassila SalomonTSTassila Salomon
- Thelma T. GonçalezTGThelma T. Gonçalez
- Ester C. SabinoESEster C. Sabino
- Liliana PreissLPLiliana Preiss
- Paula LoureiroPLPaula Loureiro
- Maria Esther LopesMLMaria Esther Lopes
- Carolina Miranda TeixeiraCTCarolina Miranda Teixeira
- Anna Barbara Carneiro‐ProiettiACAnna Barbara Carneiro‐Proietti
- Cesar de Almeida‐NetoCACesar de Almeida‐Neto
- 4 March 2021
- journal article
- research article
- Published by Wiley in Transfusion Medicine
- Vol. 31 (2) , 104-112
Abstract
Background Acquisition of HIV primary drug resistant (PDR) infection can lead to poor virologic and clinical outcomes in individuals and hampers public health efforts in epidemic control. Monitoring PDR in HIV‐positive blood donors can be used to inform nationwide trends in the spread of drug‐resistant HIV strains. Methods We conducted a cross‐sectional study using genetic sequence analysis to assess HIV pol sequences, PDR, and risk factors for infection using audio computer‐assisted structured interviews in four large blood centers in Brazil from 2007 to 2017. Results Of 716 HIV‐positive blood donors, 504 (70.4%) were successfully sequenced. HIV clade B (73.2%) was the most prevalent subtype, followed by a mix of non‐B (21.2%) sub‐types. A twofold increase (from 4% to 8%) in recombinants prevalence was observed during the study period. Sixty‐four (12.7%) presented PDR. Overall, HIV PDR prevalence remained stable during the study period. Drug resistance mutations for non‐nucleoside reverse transcriptase inhibitors were found in 39 (7.7%) donors, while for nucleoside reverse transcriptase inhibitors were found in 26 (5.1%), and for protease inhibitors in 24 (4.8%) of HIV‐infected donors. We did not find statistically significant differences in demographics, behavioural risk factors, or HIV genotypes when comparing volunteers with and without PDR. Conclusion The HIV PDR rate among donors remained stable during the study period. HIV‐positive blood donors can be an informative population to monitor primary HIV resistance and ultimately may help to increase the knowledge and awareness of HIV risk factors and PDR.Keywords
Funding Information
- National Heart, Lung, and Blood Institute
- National Institute of Mental Health
This publication has 23 references indexed in Scilit:
- The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): Twenty Years of Research to Advance Blood Product Safety and AvailabilityTransfusion Medicine Reviews, 2012
- Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011Clinical Infectious Diseases, 2012
- Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort studyThe Lancet Infectious Diseases, 2012
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLOS ONE, 2009
- Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIVJournal of the International AIDS Society, 2009
- The Challenge of HIV-1 Subtype DiversityNew England Journal of Medicine, 2008
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006
- Trends in Antiretroviral Drug Resistance and Clade Distributions Among HIV-1--Infected Blood Donors in Sao Paulo, BrazilJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet)AIDS, 2003
- A specific subtype C of human immunodeficiency virus type 1 circulates in BrazilAIDS, 2003